Momenta Pharmaceuticals (MNTA) Receives Media Sentiment Score of 0.13

Media stories about Momenta Pharmaceuticals (NASDAQ:MNTA) have trended somewhat positive on Sunday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Momenta Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.3430068564223 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Momenta Pharmaceuticals (NASDAQ MNTA) opened at $12.95 on Friday. Momenta Pharmaceuticals has a 52 week low of $11.85 and a 52 week high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. The business had revenue of $24.09 million during the quarter, compared to the consensus estimate of $29.58 million. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The firm’s revenue was down 17.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.26) EPS. sell-side analysts expect that Momenta Pharmaceuticals will post -1.16 earnings per share for the current fiscal year.

Several research firms recently issued reports on MNTA. Cowen set a $15.00 price target on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 1st. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Robert W. Baird lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the stock from $22.00 to $15.00 in a research report on Friday, October 6th. ValuEngine lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Finally, J P Morgan Chase & Co reiterated a “hold” rating and set a $14.00 price target on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating and nine have given a hold rating to the company. The company has an average rating of “Hold” and a consensus price target of $15.00.

In other news, CEO Craig A. Wheeler sold 4,116 shares of the firm’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $13.35, for a total transaction of $54,948.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Craig A. Wheeler sold 35,667 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $19.03, for a total transaction of $678,743.01. Following the transaction, the president now directly owns 286,121 shares of the company’s stock, valued at approximately $5,444,882.63. The disclosure for this sale can be found here. Insiders have sold 44,006 shares of company stock valued at $789,369 in the last ninety days. Insiders own 4.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Momenta Pharmaceuticals (MNTA) Receives Media Sentiment Score of 0.13” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/03/momenta-pharmaceuticals-mnta-receives-media-sentiment-score-of-0-13.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

What are top analysts saying about Momenta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Momenta Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit